Glenmark Pharma top pick, like Ipca Lab: Sudip Bandopadhyay

Sudip Bandopadhyay of Destimoney Securities told CNBC-TV18, "Glenmark Pharma has been one of our top picks. We also like IPCA Laboratories and we do like Indoco Remedies. It is a question of the lifecycle stage where they are in terms of various approvals in the US and developed markets which they are seeking. So, most of these companies in the midcap pharma space are at a sweet spot vis-à-vis the large cap. The large cap companies are coming under a lot of pressure. Their approvals are getting held up. They have some US FDA issues but most of the efficient and top end midcap pharma companies are doing well. They are at the right spot vis-à-vis the approvals.""It is time to focus on midcap pharma, that has been our belief. Of course, the rupee depreciation which happened over the last few days does help pharma companies because majority of their product does get exported," he said.